CinRx Pharma announced the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109.
CinRx Pharma announced the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109.
CinFina Pharma announced that it has signed an agreement with Janssen Sciences.